Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

• Bijay S. Jaiswal,

  Affiliation Department of Molecular Biology, Genentech Inc., South San Francisco, California, United States of America

  ⨯
• Vasantharajan Janakiraman,

  Affiliation Department of Molecular Biology, Genentech Inc., South San Francisco, California, United States of America

  ⨯
• Noelyn M. Kljavin,

  Affiliation Department of Molecular Biology, Genentech Inc., South San Francisco, California, United States of America

  ⨯
• Jeffrey Eastham-Anderson,

  Affiliation Department of Pathology, Genentech Inc., South San Francisco, California, United States of America

  ⨯
• James E. Cupp,

  Affiliation Department of Immunology, Genentech Inc., South San Francisco, California, United States of America

  ⨯
• Yuxin Liang,

  Affiliation Department of Molecular Biology, Genentech Inc., South San Francisco, California, United States of America

  ⨯
• David P. Davis,

  Affiliation Department of Molecular Biology, Genentech Inc., South San Francisco, California, United States of America

  ⨯
• Klaus P. Hoeflich,

  Affiliation Department of Translational Oncology, Genentech Inc., South San Francisco, California, United States of America

  ⨯
• Somasekar Seshagiri

  * E-mail: sekar@gene.com

  Affiliation Department of Molecular Biology, Genentech Inc., South San Francisco, California, United States of America

  ⨯